<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Burns Trauma</journal-id><journal-id journal-id-type="iso-abbrev">Burns Trauma</journal-id><journal-title-group><journal-title>Burns &#x00026; Trauma</journal-title></journal-title-group><issn pub-type="ppub">2321-3868</issn><issn pub-type="epub">2321-3876</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27574657</article-id><article-id pub-id-type="pmc">4964050</article-id><article-id pub-id-type="publisher-id">9</article-id><article-id pub-id-type="doi">10.1186/s41038-015-0009-5</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Interpretation for practice guidelines for prevention, diagnosis, and treatment of ventilator-associated pneumonia in burn patients by american burn association</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Luo</surname><given-names>Jie</given-names></name><address><email>lj-1988@qq.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Guo</surname><given-names>Guang-hua</given-names></name><address><email>guogh2000@hotmail.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1">Department of Burns, the First Affiliated Hospital of Nanchang University, Nanchang, 330006 Jiangxi China </aff></contrib-group><pub-date pub-type="epub"><day>1</day><month>8</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>1</day><month>8</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>3</volume><elocation-id>11</elocation-id><history><date date-type="received"><day>1</day><month>2</month><year>2015</year></date><date date-type="accepted"><day>31</day><month>5</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2015</copyright-statement><license license-type="open-access"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><p>&#x0201c;American Burn Association Practice Guidelines for Prevention, Diagnosis, and Treatment of Ventilator-Associated Pneumonia in Burn Patients&#x0201d; was published to provide recommendation for the prevention, diagnosis, and treatment of ventilator-associated pneumonia in burn patients. This article makes interpretations and conclusions for prevention, diagnosis and treatment from this guideline in the combination of domestic burn patients.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Ventilator-associated pneumonia</kwd><kwd>Inhalation injury</kwd><kwd>Burn</kwd><kwd>Burn ICU</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p>Ventilator-Associated Pneumonia (VAP) is an infectious disease of pulmonary parenchym that occurs 48 hours or longer after mechanical ventilation by means of endotracheal tubes or tracheostomy. The purpose of &#x0201c;American Burn Association Practice Guidelines for Prevention, Diagnosis, and Treatment of Ventilator-Associated Pneumonia in Burn Patients&#x0201d; is to review the published literature on ventilator-associated pneumonia (VAP) in burn patients [<xref ref-type="bibr" rid="CR1">1</xref>]. Evidence-based recommendations are provided for the prevention, diagnosis, and treatment of VAP in adult burn patients.</p></sec><sec id="Sec2"><title>Review</title><sec id="Sec3"><title>The pathogenesis and predisposing factors of VAP</title><sec id="Sec4"><title>Aspiration from respiratory and gastrointestinal colonized bacteria</title><p>VAP is often induced by microbial invasion of the sterile lower respiratory tract and lung parenchyma as patients inhale, and less by bloodstream spread or direct extension of adjacent infection. The research has demonstrated that the oropharynx is a potential reservoir for VAP after comparing bacterial DNA samples from broncheoalveolar lavages to organisms present on patients&#x02019; tongues [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. The stomach and sinuses are potential reservoirs of bacteria as well [<xref ref-type="bibr" rid="CR4">4</xref>].The stomach often gets colonized with Gram-negative bacteria during critical illness, and enteric Gram-negative bacteria are one of the most frequent microorganisms isolated from cultures of patients with VAP. Indwelling gastric tubes weaken the function of the lower esophageal sphincter during mechanical ventilation, resulting in high incidence of gastric reflux and sustained aspiration which evolve the infection in the lung parenchyma.</p></sec><sec id="Sec5"><title>Aspiration from secretions of upper respiratory tract</title><p>Bypassing the glottis barrier, with aspiration of contaminated secretions around the endotracheal tube cuff, intubation and mechanical ventilation weaken the normal respiratory tract defenses against infection. The patients with mechanical ventilation are unable to clear their own secretions, which has impaired mucocilary clearance, and are subjected to repeated infection inspite of suctioning. The incidence of VAP increases with the duration of mechanical ventilation. In the early period of ventilation, the risk of VAP increase fastestly, at an estimated incidence of 3 % per day during the first 5 days, decreasing to 2 % per day on days 5 to 10, and to 1 % per day after 10 days [<xref ref-type="bibr" rid="CR5">5</xref>].</p></sec><sec id="Sec6"><title>Burn and inhalation injury</title><p>Burn injury is a strong predisposing factor for VAP. Nearly 10 to 20 % of burn patients are also sufferers of inhalation injury, and the risk increases with increasing burn size [<xref ref-type="bibr" rid="CR6">6</xref>]. Inhalation injury is a potential signal of prolonged ventilator dependence, increased duration of hospitalization, and likelihood of fatality. In the patients with large burns, increased capillary permeability occurs not only at the injured sites, but also in remote organs. Just as the edema in the burn wound, the respiratory mucosa would develop into edema caused by an inflammatory cascade [<xref ref-type="bibr" rid="CR7">7</xref>]. The exudation of plasma proteins from the pulmonary microvasculature into the interstitial and alveolar spaces leads to secretion formation which congeal with neutrophils and necrotic cellular debris to form fibrin casts, partially or fully obstructing the airways and causing bronchoconstriction. Induced by the acute inflammatory response, release of the proteolytic enzymes and oxidants destroys the lung parenchyma and increases the microvascular permeability, further accelerating edema formation and decreasing gas exchange [<xref ref-type="bibr" rid="CR8">8</xref>]. Alveloar collapse and decrease in lung compliance result from diminished surfactant.</p><p>In conclusion, burn patients with inhalation injury develop pulmonary complications frequently, including reactive airway disease, acute respiratory distress syndrome (ARDS) and pneumonia. VAP is a common complication of ARDS: about 34 to 70 % of patients with ARDS develop VAP [<xref ref-type="bibr" rid="CR9">9</xref>].Autopsy demonstrated that nearly 73 % of patients with diagnosis of ARDS also have histological evidence of pneumonia [<xref ref-type="bibr" rid="CR10">10</xref>].</p></sec><sec id="Sec7"><title>Else predisposing factors</title><p>Host factors includes burn/trauma, severe critical illness, age&#x0003e;60 years, ARDS, chronic obstructive pulmonary disease, serum albumin&#x0003c;2.2g/dL, multiple organ dysfunction, large-volume gastric aspiration, gastric colonization, elevated pH, Upper respiratory tract colonization and sinusitis. Intervention factors includes mechanical ventilation&#x0003e;2 d, re-intubation, supine head position, paralytic agents, continuous intravenous sedation, positive end-expiratory pressure, frequent ventilator circuit changes, &#x0003e;4 units of blood products transfused, histamine 2-blockers, antacids, nasogastric tube, prior antibiotic therapy, transport out of the intensice care unit [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>].</p></sec></sec><sec id="Sec8"><title>Prevention strategies of VAP</title><sec id="Sec9"><title>Necessity of mechanical ventilation</title><p>In General, unnecessary intubation and mechanical ventilation should be avoided as much as possible, because this process can increase the risk of VAP 6 to 21-fold. However, when the necessary intubation is needed, it should be performed under controlled conditions as much as possible. The research shows that intubations in emergency department lead to higher incidence of VAP than in the ICU setting [<xref ref-type="bibr" rid="CR13">13</xref>]. Furthermore, VAP incidence can be reduced when accidental tube dislodgement and emergency reintubation are avoided. In order to limit reintubation for laryngeal edema and postextubation stridor, presence of a cuff leak over 10 to 15 % has been suggested as a simple screnning test whether reintubation is needed or not, and that is particularly useful in the burn patients with extensivr head and neck edema following burn resuscitation. The recent study has showed that daily interruption of sedation and weaning protocols can not only reduce the duration of mechanical ventilation in ICU patients, but also improve the extubation rates without an increase in reintubation rates [<xref ref-type="bibr" rid="CR14">14</xref>].</p></sec><sec id="Sec10"><title>Specialized endotracheal tubes</title><p>Because of reducing the bacterial inoculum, specialized endotracheal tubes may prove particularly beneficial in patients with prolonged mechanical ventilation. In several studies, tubes with continuous aspiration of subglottic secretions have reduced the incidence of early-onset VAP [<xref ref-type="bibr" rid="CR15">15</xref>]. Because of the broad-spectrum antimicrobial activity of silver, silver impregnated endotracheal tubes have potential applications in theory. Silver-coated endotracheal tubes were used in a randomized trial of 9417 patients across 54 centers in North America. The results show that a 35.9 % relative risk reduction in VAP which reduce the incidence of VAP from 7,5 % to 4.8 % in a mixed ICU population of patients expected to require intubation for over 24 hours [<xref ref-type="bibr" rid="CR16">16</xref>].</p></sec><sec id="Sec11"><title>Reducing aspiration from gastrointestinal sources</title><p>As an increased risk of aspiration of gastric contents, the administration of enteral nutrition with supine position are thougt to be a risk factor for the development of VAP [<xref ref-type="bibr" rid="CR17">17</xref>]. The research has demonstrated that patients administrated with enteral nutrition in the supine position have as much as a 50 % incidence of VAP compared to 5 % in those kept in the semirecumbent position [<xref ref-type="bibr" rid="CR18">18</xref>]. Therefore, burn patients with maintaining mechanical ventilation should be kept in the semirecumbent position instead of the supine position especially when administrated with enteral nutrition.</p></sec><sec id="Sec12"><title>Use of prophylactic antibiotic</title><p>In several studies, modulation of oropharyngeal colonization has also been shown to reduce the incidence of VAP by using combinations of oral antibiotics, with or without systemic therapy, or selective decontamination of the gastrointestinal tract (SDD) [<xref ref-type="bibr" rid="CR19">19</xref>]. In the areas where the incidence of VAP is considerablely high, the idea of prophylactic antibiotics to decrease the incidence is similar to SDD. Trimethoprim-sulfamethoxazole (TMP-SMX) could obviously reduce the incidence of VAP in large burn patients which is demonstrated by several researches [<xref ref-type="bibr" rid="CR20">20</xref>]. However, due to the high endemic levels of antibiotic resistance, the benefits of prophylactic antibiotics for VAP have been considerablely low in ICUs. In this circumstance, prophylactic antibiotics seemed to increase the selective pressure for antibiotic-resistant microorganisms resulting in strong resistance of pathogenic bacteria. Thus, routine prophylactic antibiotics should not be recommended in hospital where there are high levels of antibiotic resistance, although the use of prophylactic antibiotics can reduce early-onset VAP.</p></sec><sec id="Sec13"><title>Reducing oropharyngeal bacterial colonization</title><p>Chlorhexidine oral rinse is a simple and cost-effective prevention strategy for VAP in many different patient population which has been shown in many studies. A 58 % reduction in incidences of pneumonia has been found by Houston et al. [<xref ref-type="bibr" rid="CR21">21</xref>] in patients intubated&#x0003e;24 h with chlorhexidine oral rinse. In critically ill patients ventilated&#x0003e;48 h, there is also a 65 % reduction in VAP by the same way [<xref ref-type="bibr" rid="CR22">22</xref>]. Recently, the use of selective oropharyngeal decontamination (SOD) has been advocated. However, a recent meta-analysis demonstrated that SOD significantly reduces the incidence of lower respiratory tract infections but does not reduce mortality [<xref ref-type="bibr" rid="CR23">23</xref>].</p></sec><sec id="Sec14"><title>Restrictive blood transfusion</title><p>As we all know, postinjury immunosuppression is considered as a complication of severe burn injury. Common therapies can add to the immune compromised state, such as blood transfusion. Transfusion, which is demonstrated by several studies, can increased the risk for VAP [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. The American Burn Association has found a 13 % increased risk of infection with each unit of blood transfused in patients with burn injuries&#x0003e;20 % TBSA and 42 % of those transfused developed into VAP [<xref ref-type="bibr" rid="CR25">25</xref>]. Thus, the restrictive blood transfusion policy should be applied to burn patients in order to reduce infections.</p></sec><sec id="Sec15"><title>Intensive insulin therapy</title><p>Controlling blood glucose levels (to levels 4.4-6.1mmol/L) by intensive insulin therapy can decrease mortality in surgical ICU patients which is pulished as a landmark trial in 2001 [<xref ref-type="bibr" rid="CR26">26</xref>]. However, the subsequent trials did not confirm this benefit. Recently, Hemmila et al. share their experiences of intensive insulin therapy in burn patients. Their adoption of protocol (to levels&#x0003c;7.8mmol/L) did decrease VAP rate with no impact on mortality [<xref ref-type="bibr" rid="CR27">27</xref>]. The potential benefit of intensive insulin therapy in burn patients needs to be confirmed in more large trials. Before that, the protocol of intensive insulin therapy is an option in burn patients with ventilation.</p></sec><sec id="Sec16"><title>Control environmental infection</title><p>The environment, healthcare devices, and even staff can all serve as sources of infection. Bacterial colonization of the ventilator circuit may also lead to VAP. By institution of an infection control protocol , the U.S. military has decreased the incidence of VAP in Irap recently, which includs hand hygiene, chlorhexidine oral care, contact barrier precautions, patient and staff cohorting, and reducing the duration and spectrum of surgical antimicrobial prophylaxis [<xref ref-type="bibr" rid="CR28">28</xref>].</p></sec></sec><sec id="Sec17"><title>Diagnosis of VAP</title><p>As to the diagnosis, there is no clinical gold standard existing for the diagnosis of VAP. Many patients with the clinical diagnosis of pneumonia may have no infectious etiologies, while as many as 66 % of patients with the clinical diagnosis of VAP did not meet the microbiologic criteria for infection. In order to improve the ability to diagnosis VAP, the scoring systems such as the U.S. centers for disease control and prevention (CDC) Criteria and the Clinical Pulmonary Infection Score (CPIS) have been established, which combine clinical, radiographic, physiologic (PaO2/FiO2), and microbiologic data, to improve the specificity of VAP diagnosis. An initial score&#x0003e;6 and a persistently elevated CPIS&#x0003e;6 after 3 days of empiric treatment are strongly related to VAP in mediacal and ICU patients. However, the CPIS scale is not able to differentiate inflammation from infection, a differentiation that can be definitively made by quantitative culture (Table <xref rid="Tab1" ref-type="table">1</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>The clinical pulmonary infection score (CPIS) [<xref ref-type="bibr" rid="CR36">36</xref>]</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Componet</th><th>Value</th><th>Points</th></tr></thead><tbody><tr><td>Temperature C</td><td>&#x02265;36.5 and &#x02264;38.4</td><td>0</td></tr><tr><td/><td>&#x02265;38.5 and &#x02264;38.9</td><td>1</td></tr><tr><td/><td>&#x02265;39.0 and &#x02264;36.0</td><td>2</td></tr><tr><td>Blood leukocytes per mm<sup>3</sup>
</td><td>&#x02265;4000 and &#x02264;11,000</td><td>0</td></tr><tr><td/><td>&#x0003c;4000 or &#x0003e;11,000</td><td>1</td></tr><tr><td>Tracheal secretions</td><td>Few</td><td>0</td></tr><tr><td/><td>Moderate</td><td>1</td></tr><tr><td/><td>Large</td><td>2</td></tr><tr><td/><td>Purulent</td><td>+1</td></tr><tr><td>Oxygenation PaO2/FiO2</td><td>&#x0003e;240 or presence of ARDS</td><td>0</td></tr><tr><td/><td>&#x02264;240 and absence of ARDS</td><td>2</td></tr><tr><td>Chest radiograph</td><td>No infiltrate</td><td>0</td></tr><tr><td/><td>Pathy or diffuse infiltrate</td><td>1</td></tr><tr><td/><td>Localized infiltrate</td><td>2</td></tr></tbody></table></table-wrap></p><p>In contrast to the CPIS, it is a recommended strategy to obtain a lower airway quantitative culture when VAP is suspected, using broncheoalvolar lavage (BAL), protected specimen brush, or a nonbronchoscopic technique (so-called mini BAL). The quantitative strategy can increase specificity of diagnosis and identify the responsible organisms, and reduce the extended use of broad-spectrum antimicrobials in the ICU. Most authors use 1*10 5CFU/ml as BAL threshold, however, several studies in the trauma population have used a BAL threshold of 1*10 5 CFU/ml to limit unnessary administration of systemic antibiotics and rates of VAP recurrence have no significantly differences. Besides, BAL should not be considered as 100 % accurate in identifying the infective bacterium, but could show good correlation [<xref ref-type="bibr" rid="CR29">29</xref>].</p></sec><sec id="Sec18"><title>Treatment of VAP</title><sec id="Sec19"><title>Early Use of broad-spectrum antibiotic coverage</title><p>Many studies have shown that a delay in the initiation of appropriate antibiotic therapy for patients with VAP has association with increased morbidity, cost of care, and mortality whether VAP is early or late in onset [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. Therefore, once a patient is diagnosed with VAP, broad-spectrum antibiotic therapy should be adopted immediately targeting specific likely pathogens based on timing of VAP onset and modified by knowledge of local patterns of antibiotic resistance. Importantly, a quantitative culture should be obtained before adoption of antibiotics, and diagnostic threshold should be lowed if the culture is obtained after administration of antibiotics.</p></sec><sec id="Sec20"><title>De-escalation of broad-spectrum antibiotic</title><p>If quantiative culture was obtained, antimicrobial spectrum should be narrowed according to microbiologic results and sensitivities, known as de-escalation. Use of ICU specific, broad-spectrum, empiric therapy is able to lead to a significant increase in the administration of appropriate antimicrobial treatment, a decrease in development of secondary episodes of antibiotic-resistant VAP, and a significant reduction in the duration of antibiotic treatment [<xref ref-type="bibr" rid="CR32">32</xref>]. Furthermore, a recent international consensus conference agreed that the use of broad-spectrum antibiotics for &#x0003c;48h would not induce a significant risk of multiple drug resistance (MDR).Therefore, de-escalation of broad-spectrum antibiotic should be adopted as soon as quantitative culture results are known [<xref ref-type="bibr" rid="CR33">33</xref>].</p></sec><sec id="Sec21"><title>Antibiotic rotation</title><p>Antibiotic rotation has been evaluated and adopted by many doctors, although no study has specifically examined its role in burns. Several evaluation researches have showed a decreased incidence of MDR bacteria and mortality benefit with the adoption of antibiotic rotation [<xref ref-type="bibr" rid="CR32">32</xref>]. However, antibiotic rotation should be considered as an option for burn centers to reduce the spread of MDR bacteria until further burn unit specific data become available.</p></sec><sec id="Sec22"><title>Duration of antibiotic treatment</title><p>It is suggested by recent data from many other trails that antibiotics can be stopped once clinical signs of infection have resolved. This may also decrease the incidence of secondary pneumonias with MDR organisms. Dennesen et al. have reported that most of the clinical signs of pneumonia have resolved by 6 days of therapy. Another randomized trial in France demonstrated that there is no difference in mortality or recurrent infection in patients treated with an 8 day course of antibiotics compared with those treated with a 15 day course [<xref ref-type="bibr" rid="CR34">34</xref>]. Additonally, those treated with 8 days of antibiotics had a lower incidence of multiresistant pathogens if a recurrent infection developed. Notebly, if the original infecting organism was a nonlactose fermenting Gram-negative bacilli such as Acinetobacter baumanii, those treated with an 8 day course had a higher pulmonary infection recurrence rate [<xref ref-type="bibr" rid="CR35">35</xref>]. Similar to the strong virulence of nonlactose fermenting Gram-negative bacilli, MRSA pneumonias are often quite virulent, with demands for longer ICU and ventilator support. Thus, unless caused by MRSA or nonlactose fermenting Gram-nagative rods, in which case the treatment of 15 day course is recommended, antibiotic treatment for VAP should be limited with 8 days.</p></sec></sec></sec><sec id="Sec23" sec-type="conclusion"><title>Conclusion</title><p>Although the research on VAP has made obvious progress in recent years, there is still no clinical gold standard existing for the diagnosis of VAP that requires further researched. The recommendations in these guidelines are derived from available general critical care and burn literature. Although most of the data were obtained by study of medical, surgical, and trauma patients these finding are also applicable to critically ill burn patients with mechanical ventilation.</p></sec></body><back><fn-group><fn><p><bold>Competing interest</bold></p><p>The authors declare that they have no competing interests.</p></fn><fn><p><bold>Authors&#x02019; contribution</bold></p><p>LJ searched and organized the literature, and drafted the manuscript. GGH conceived of the subject and helped to revise the article. Both authors read and approved the final manuscript.</p></fn></fn-group><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mosier</surname><given-names>MJ</given-names></name><name><surname>Pham</surname><given-names>TN</given-names></name></person-group><article-title>American burn association practice guidelines for prevention, diagnosis, and treatment of ventilator-associated pneumonia(VAP) in burn patients[J]</article-title><source>J Burn Care Res</source><year>2009</year><volume>30</volume><issue>6</issue><fpage>910</fpage><lpage>928</lpage><pub-id pub-id-type="pmid">19826271</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeRiso</surname><given-names>AJ</given-names></name><name><surname>Ladowski</surname><given-names>JS</given-names></name><name><surname>Dillon</surname><given-names>TA</given-names></name><name><surname>Justice</surname><given-names>JW</given-names></name><name><surname>Peterson</surname><given-names>AC</given-names></name></person-group><article-title>Chlorhexidine gluconate 0.12% oral rinse reduces the incidence of total nosocomial respiratory infection and nonprophylactic systemic antibiotic use in patients undergoing heart surgery[J]</article-title><source>Chest</source><year>1996</year><volume>109</volume><issue>6</issue><fpage>1556</fpage><lpage>1561</lpage><pub-id pub-id-type="doi">10.1378/chest.109.6.1556</pub-id><pub-id pub-id-type="pmid">8769511</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seguin</surname><given-names>P</given-names></name><name><surname>Tanguy</surname><given-names>M</given-names></name><name><surname>Laviolle</surname><given-names>B</given-names></name><name><surname>Tirel</surname><given-names>O</given-names></name><name><surname>Malledant</surname><given-names>Y</given-names></name></person-group><article-title>Effect of oropharyngcal decontamination by povidone-iodine on ventilator-associated pneumonia in patients with head trauma[J]</article-title><source>Crit Care Med</source><year>2006</year><volume>34</volume><issue>5</issue><fpage>1514</fpage><lpage>1519</lpage><pub-id pub-id-type="doi">10.1097/01.CCM.0000214516.73076.82</pub-id><pub-id pub-id-type="pmid">16540962</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daniel</surname><given-names>DS</given-names></name><name><surname>Ng</surname><given-names>YK</given-names></name><name><surname>Chua</surname><given-names>EL</given-names></name><name><surname>Arumugam</surname><given-names>Y</given-names></name><name><surname>Wong</surname><given-names>WL</given-names></name><name><surname>Kumaran</surname><given-names>JV</given-names></name></person-group><article-title>Isolation and identification of gastrointestinal microbiota from the short-nosed friut bat Cynopterus brachyotis brachyotis[J]</article-title><source>Microbiol Res</source><year>2013</year><volume>168</volume><issue>8</issue><fpage>485</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.1016/j.micres.2013.04.001</pub-id><pub-id pub-id-type="pmid">23706760</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beheshti</surname><given-names>M</given-names></name><name><surname>Talebi</surname><given-names>M</given-names></name><name><surname>Ardebili</surname><given-names>A</given-names></name><name><surname>Ardebili</surname><given-names>A</given-names></name><name><surname>Bahador</surname><given-names>A</given-names></name><name><surname>Lari</surname><given-names>AR</given-names></name></person-group><article-title>Detection of AdeABC efflux pump genes in tetracycline-resistant Acinebtobacter baumannii isolates from burn and ventilator-associated pneumonia patients.[J]</article-title><source>J Pharm Bioallied Sci</source><year>2014</year><volume>6</volume><issue>4</issue><fpage>229</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.4103/0975-7406.142949</pub-id><pub-id pub-id-type="pmid">25400404</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edelman</surname><given-names>DA</given-names></name><name><surname>Khan</surname><given-names>N</given-names></name><name><surname>Kempf</surname><given-names>K</given-names></name><name><surname>White</surname><given-names>MT</given-names></name></person-group><article-title>Pneumonia after inhalation injury[J]</article-title><source>J Burn Car Rehabil</source><year>2007</year><volume>28</volume><issue>2</issue><fpage>241</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1097/BCR.0B013E318031D049</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname><given-names>RA</given-names></name><name><surname>Burke</surname><given-names>AS</given-names></name><name><surname>Soejima</surname><given-names>K</given-names></name><name><surname>Murakami</surname><given-names>K</given-names></name><name><surname>Katahira</surname><given-names>J</given-names></name><name><surname>Traber</surname><given-names>LD</given-names></name><etal/></person-group><article-title>Airway obstruction in sheep with burn and smoke inhalation injuries[J]</article-title><source>Am J Respir Cell Mol Biol</source><year>2003</year><volume>29</volume><issue>3</issue><fpage>295</fpage><lpage>302</lpage><pub-id pub-id-type="doi">10.1165/rcmb.4860</pub-id><pub-id pub-id-type="pmid">12936906</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Virag</surname><given-names>L</given-names></name></person-group><article-title>Poly(ADP-ribosyl) ation in asthma and other lung disease[J]</article-title><source>Pharmacol Res</source><year>2005</year><volume>52</volume><issue>1</issue><fpage>83</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1016/j.phrs.2005.02.012</pub-id><pub-id pub-id-type="pmid">15911336</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wunderink</surname><given-names>RG</given-names></name><name><surname>Waterer</surname><given-names>GW</given-names></name></person-group><article-title>Pneumonia complicating the actue respiratory distress syndrome[J]</article-title><source>Semin Respir Crit Care Med</source><year>2002</year><volume>23</volume><issue>5</issue><fpage>443</fpage><lpage>448</lpage><pub-id pub-id-type="doi">10.1055/s-2002-35715</pub-id><pub-id pub-id-type="pmid">16088638</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bell</surname><given-names>RC</given-names></name><name><surname>Coalson</surname><given-names>JJ</given-names></name><name><surname>Smith</surname><given-names>JD</given-names></name><name><surname>Johanson</surname><given-names>WG</given-names><suffix>Jr</suffix></name></person-group><article-title>Multiple organ system failure and infection in adult respiratory distress syndrome[J]</article-title><source>Ann Intern Medd</source><year>1983</year><volume>99</volume><issue>3</issue><fpage>293</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-99-3-293</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubenstein</surname><given-names>E</given-names></name><name><surname>Cammarata</surname><given-names>S</given-names></name><name><surname>Oliphant</surname><given-names>T</given-names></name><name><surname>Wunderink</surname><given-names>R</given-names></name></person-group><article-title>Linezolid versus vancomycin in the treatment of hospitalized patinets with nosocomial pneumonia:a randomized double-blind multicenter study[J]</article-title><source>Clin Infect Dis</source><year>2001</year><volume>32</volume><fpage>402</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.1086/318486</pub-id><pub-id pub-id-type="pmid">11170948</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heyland</surname><given-names>DK</given-names></name><name><surname>Dhaliwal</surname><given-names>R</given-names></name><name><surname>Drover</surname><given-names>JW</given-names></name><name><surname>Gramlich</surname><given-names>L</given-names></name><name><surname>Dodek</surname><given-names>P</given-names></name></person-group><article-title>Canadian Critical Care Clinical Practice Guidelines Committee. Canadian clinical practice guidelines for nutrition support in mechanically ventilated, critically ill adult patients[J]</article-title><source>JPEN J Perenter Enteral Nutr</source><year>2003</year><volume>27</volume><issue>5</issue><fpage>355</fpage><lpage>373</lpage><pub-id pub-id-type="doi">10.1177/0148607103027005355</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eckert</surname><given-names>M</given-names></name><name><surname>Davis</surname><given-names>K</given-names></name><name><surname>Reed</surname><given-names>RI</given-names></name><name><surname>Esposito</surname><given-names>TJ</given-names></name><name><surname>Santaniello</surname><given-names>JM</given-names></name><name><surname>Poulakidas</surname><given-names>S</given-names></name><etal/></person-group><article-title>Ventilator-associated pneumonia, like real estate:location really matters[J]</article-title><source>J Trauma</source><year>2006</year><volume>60</volume><issue>1</issue><fpage>104</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1097/01.ta.0000197376.98296.7c</pub-id><pub-id pub-id-type="pmid">16456443</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robertson</surname><given-names>TE</given-names></name><name><surname>Sona</surname><given-names>C</given-names></name><name><surname>Schallom</surname><given-names>L</given-names></name><name><surname>Buckles</surname><given-names>M</given-names></name><name><surname>Cracchiolo</surname><given-names>L</given-names></name><name><surname>Schuerer</surname><given-names>D</given-names></name><etal/></person-group><article-title>Improved extubation rates and carlier liberation from mechanical ventilation with implementation of a daily spontaneous-breathing trail protocol[J]</article-title><source>J Am Coll Surg</source><year>2008</year><volume>206</volume><fpage>489</fpage><lpage>495</lpage><pub-id pub-id-type="doi">10.1016/j.jamcollsurg.2007.08.022</pub-id><pub-id pub-id-type="pmid">18308220</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramirez</surname><given-names>P</given-names></name><name><surname>Ferrer</surname><given-names>M</given-names></name><name><surname>Torres</surname><given-names>A</given-names></name></person-group><article-title>Prevention measures for ventilator-associated pneumonia:a new focus on the endotracheal tube[J]</article-title><source>Curr Opin Infect Dis</source><year>2007</year><volume>20</volume><issue>2</issue><fpage>190</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1097/QCO.0b013e328014daac</pub-id><pub-id pub-id-type="pmid">17496579</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kollef</surname><given-names>MH</given-names></name><name><surname>Afessa</surname><given-names>B</given-names></name><name><surname>Anzueto</surname><given-names>A</given-names></name><etal/></person-group><article-title>Sliver-coated endotrachael tubes and incidence of ventilator-associtated pneumonia:The NASCENT randomized trial[J]</article-title><source>JAMA</source><year>2008</year><volume>300</volume><issue>7</issue><fpage>805</fpage><lpage>813</lpage><pub-id pub-id-type="doi">10.1001/jama.300.7.805</pub-id><pub-id pub-id-type="pmid">18714060</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Righi</surname><given-names>E</given-names></name><name><surname>Aggazzotti</surname><given-names>G</given-names></name><name><surname>Ferrari</surname><given-names>E</given-names></name><etal/></person-group><article-title>Trends in ventilator-associated pneumonia:impact of a ventilator care bundle in an Italian tertiary care hospital intensive care unit[J]</article-title><source>Am J Infect Control</source><year>2014</year><volume>42</volume><issue>12</issue><fpage>1312</fpage><lpage>1316</lpage><pub-id pub-id-type="doi">10.1016/j.ajic.2014.08.009</pub-id><pub-id pub-id-type="pmid">25444306</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Correa Rde</surname><given-names>A</given-names></name><name><surname>Luna</surname><given-names>CM</given-names></name><name><surname>Dos Anjos</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Quantitative culture of endotracheal aspirate and BAL fluid samples in the management of patients with ventilator-associated pneumonia:a randomized clinical trial[J]</article-title><source>J Bras Pneumol</source><year>2014</year><volume>40</volume><issue>6</issue><fpage>643</fpage><lpage>651</lpage><pub-id pub-id-type="doi">10.1590/S1806-37132014000600008</pub-id><pub-id pub-id-type="pmid">25610505</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanizaki</surname><given-names>S</given-names></name><name><surname>Suzuki</surname><given-names>K</given-names></name></person-group><article-title>No influence of burn size on ventilator-associated pneumonia in burn patients with inhalation injury[J]</article-title><source>Burns</source><year>2012</year><volume>38</volume><issue>8</issue><fpage>1109</fpage><lpage>1113</lpage><pub-id pub-id-type="doi">10.1016/j.burns.2012.08.008</pub-id><pub-id pub-id-type="pmid">22999207</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kimura</surname><given-names>A</given-names></name><name><surname>Mochizuki</surname><given-names>T</given-names></name><name><surname>Nishizawa</surname><given-names>K</given-names></name><name><surname>Mashiko</surname><given-names>K</given-names></name><name><surname>Yamamoto</surname><given-names>Y</given-names></name><name><surname>Otsuka</surname><given-names>T</given-names></name></person-group><article-title>Trimethoprim-sulframethoxazole for the prevention of methicillin-resistant Snaphylococcus aureus pneumonia in severely burned patients[J]</article-title><source>J Trauma</source><year>1988</year><volume>45</volume><issue>2</issue><fpage>383</fpage><lpage>387</lpage><pub-id pub-id-type="doi">10.1097/00005373-199808000-00032</pub-id><pub-id pub-id-type="pmid">9715201</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Houston</surname><given-names>S</given-names></name><name><surname>Hougland</surname><given-names>P</given-names></name><name><surname>Anderson</surname><given-names>JJ</given-names></name><name><surname>LaRocco</surname><given-names>M</given-names></name><name><surname>Kennedy</surname><given-names>V</given-names></name><name><surname>Gentry</surname><given-names>LO</given-names></name></person-group><article-title>Effectiveness of 0.12% cholhexidine gluconate oral rinse in reducing prevalence of nosocomia pneumonia in patients undergoing heart surgery[J]</article-title><source>Am J Crit Care</source><year>2002</year><volume>11</volume><issue>6</issue><fpage>567</fpage><lpage>570</lpage><pub-id pub-id-type="pmid">12425407</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koeman</surname><given-names>M</given-names></name><name><surname>van der Ven</surname><given-names>AJ</given-names></name><name><surname>Hak</surname><given-names>E</given-names></name><name><surname>Joore</surname><given-names>HC</given-names></name><name><surname>Kaasjager</surname><given-names>K</given-names></name><name><surname>de Smet</surname><given-names>AG</given-names></name><etal/></person-group><article-title>Oral decontamination with chlorhexadine reduces the incidence of ventilator-associated pneumonia[J]</article-title><source>Am J Respir Crit Care Med</source><year>2006</year><volume>173</volume><issue>12</issue><fpage>1348</fpage><lpage>1355</lpage><pub-id pub-id-type="doi">10.1164/rccm.200505-820OC</pub-id><pub-id pub-id-type="pmid">16603609</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silvestri</surname><given-names>L</given-names></name><name><surname>van Saene</surname><given-names>HK</given-names></name><name><surname>Zandstra</surname><given-names>DF</given-names></name><name><surname>Viviani</surname><given-names>M</given-names></name><name><surname>Gregori</surname><given-names>D</given-names></name></person-group><article-title>SDD, SOD or oropharyngeal chlorhexidine to prevent pneumonia and to reduce mortality in ventilated patients:which manoeuvre is evidence based?[f]</article-title><source>Intensive Care Med</source><year>2010</year><volume>36</volume><issue>8</issue><fpage>1436</fpage><lpage>1437</lpage><pub-id pub-id-type="doi">10.1007/s00134-010-1809-5</pub-id><pub-id pub-id-type="pmid">20237766</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shorr</surname><given-names>AF</given-names></name><name><surname>Duh</surname><given-names>MS</given-names></name><name><surname>Kelly</surname><given-names>KM</given-names></name><name><surname>Kollef</surname><given-names>MH</given-names></name></person-group><article-title>Red blood cell transfusion and ventilator-associated pneumonia:a potential link[J]?</article-title><source>Crit Care Med</source><year>2004</year><volume>32</volume><issue>3</issue><fpage>666</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.1097/01.CCM.0000114810.30477.C3</pub-id><pub-id pub-id-type="pmid">15090945</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palmieri</surname><given-names>TL</given-names></name><name><surname>Caruso</surname><given-names>DM</given-names></name><name><surname>Foster</surname><given-names>KN</given-names></name><name><surname>Cairns</surname><given-names>BA</given-names></name><name><surname>Peck</surname><given-names>MD</given-names></name><name><surname>Gamelli</surname><given-names>RL</given-names></name><etal/></person-group><article-title>Effect of blood transfusion on outcome after major burn injury:a multicenter study[J]</article-title><source>Crit Care Med</source><year>2006</year><volume>34</volume><issue>6</issue><fpage>1602</fpage><lpage>1607</lpage><pub-id pub-id-type="doi">10.1097/01.CCM.0000217472.97524.0E</pub-id><pub-id pub-id-type="pmid">16607231</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van den Berghc</surname><given-names>G</given-names></name><name><surname>Wouters</surname><given-names>P</given-names></name><name><surname>Weekers</surname><given-names>F</given-names></name><name><surname>Verwaest</surname><given-names>C</given-names></name><name><surname>Bruyninckx</surname><given-names>F</given-names></name><name><surname>Schetz</surname><given-names>M</given-names></name><etal/></person-group><article-title>Intensive insulin therapy in the critically ill patients[J]</article-title><source>N Engl J Med</source><year>2001</year><volume>345</volume><issue>19</issue><fpage>1359</fpage><lpage>1367</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa011300</pub-id><pub-id pub-id-type="pmid">11794168</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hemmila</surname><given-names>MR</given-names></name><name><surname>Taddonio</surname><given-names>MA</given-names></name><name><surname>Arbabi</surname><given-names>S</given-names></name><etal/></person-group><article-title>Intensive insulin therapy is associated with reduced infectious complications in burn patients[J]</article-title><source>Surgery</source><year>2008</year><volume>144</volume><issue>4</issue><fpage>629</fpage><lpage>635</lpage><pub-id pub-id-type="doi">10.1016/j.surg.2008.07.001</pub-id><pub-id pub-id-type="pmid">18847648</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landrum</surname><given-names>ML</given-names></name><name><surname>Murray</surname><given-names>CK</given-names></name></person-group><article-title>Ventialtor associated pneumonia in a military deployed setting:the impact of an aggressive infection control program[J]</article-title><source>J Trauma</source><year>2008</year><volume>64</volume><issue>2</issue><fpage>123</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1097/TA.0b013e31816086dc</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barret</surname><given-names>JP</given-names></name><name><surname>Ramzy</surname><given-names>PI</given-names></name><name><surname>Wolf</surname><given-names>SE</given-names></name><name><surname>Herndon</surname><given-names>DN</given-names></name></person-group><article-title>Sensitivity and specificity of bronchoalveolar lavage and protected bronchial brush in the diagnosis of pneumonia in pediatric burn patients[J]</article-title><source>Arch Surg</source><year>1999</year><volume>134</volume><issue>11</issue><fpage>1243</fpage><lpage>1247</lpage><pub-id pub-id-type="doi">10.1001/archsurg.134.11.1243</pub-id><pub-id pub-id-type="pmid">10555640</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krdzalic</surname><given-names>A</given-names></name><name><surname>Kosjerina</surname><given-names>A</given-names></name><name><surname>Jahic</surname><given-names>E</given-names></name><name><surname>Rifatbegovic</surname><given-names>Z</given-names></name><name><surname>Krdzalic</surname><given-names>G</given-names></name></person-group><article-title>Influence of Remifentanil/Propofol Anesthesia on Ventilator-associated Pneumonia occurence after major cardiac surgery[J]</article-title><source>Med Arch</source><year>2013</year><volume>67</volume><issue>6</issue><fpage>407</fpage><lpage>409</lpage><pub-id pub-id-type="doi">10.5455/medarh.2013.67.407-409</pub-id><pub-id pub-id-type="pmid">25568509</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huzar</surname><given-names>TF</given-names></name><name><surname>Cross</surname><given-names>JM</given-names></name></person-group><article-title>Ventilaor &#x02013;associated pneumonia in burn patients: acause or consequence of critical illness[J].Expert Rev</article-title><source>Respir Med</source><year>2011</year><volume>5</volume><issue>5</issue><fpage>663</fpage><lpage>673</lpage></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dellit</surname><given-names>TH</given-names></name><name><surname>Chan</surname><given-names>DJ</given-names></name><name><surname>Skerrett</surname><given-names>SJ</given-names></name><name><surname>Nathens</surname><given-names>AB</given-names></name></person-group><article-title>Development of a guideline for the management of ventilator associated pneumonia based on local microbiolgic findings and impact of the guideline on antimicrobial use pratices[J]</article-title><source>Infect Control Hosp Epidemiol</source><year>2008</year><volume>29</volume><issue>6</issue><fpage>525</fpage><lpage>533</lpage><pub-id pub-id-type="doi">10.1086/588160</pub-id><pub-id pub-id-type="pmid">18510462</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rello</surname><given-names>J</given-names></name><name><surname>Paiva</surname><given-names>JA</given-names></name><name><surname>Baraibar</surname><given-names>J</given-names></name><name><surname>Barcenilla</surname><given-names>F</given-names></name><name><surname>Bodi</surname><given-names>M</given-names></name><name><surname>Castander</surname><given-names>D</given-names></name><etal/></person-group><article-title>International conference for the development of consensus on the diagnosis and treatment of ventilator-associated pneumonia[J]</article-title><source>Chest</source><year>2001</year><volume>120</volume><issue>3</issue><fpage>955</fpage><lpage>970</lpage><pub-id pub-id-type="doi">10.1378/chest.120.3.955</pub-id><pub-id pub-id-type="pmid">11555535</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dennesen</surname><given-names>PJ</given-names></name><name><surname>Van der Ven</surname><given-names>AJ</given-names></name><name><surname>Kessels</surname><given-names>AG</given-names></name><name><surname>Ramsay</surname><given-names>G</given-names></name><name><surname>Bonten</surname><given-names>M</given-names></name></person-group><article-title>Resolution of infectious parameters after microbial therapy in patients with ventilator-associated pneumonia[J]</article-title><source>Am J Respir Crit Care Med</source><year>2001</year><volume>163</volume><issue>6</issue><fpage>1371</fpage><lpage>1375</lpage><pub-id pub-id-type="doi">10.1164/ajrccm.163.6.2007020</pub-id><pub-id pub-id-type="pmid">11371403</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mc Govern Murphy</surname><given-names>F</given-names></name><name><surname>Raymond</surname><given-names>M</given-names></name><name><surname>Menard</surname><given-names>PA</given-names></name><name><surname>Bejar-Ardiles</surname><given-names>KR</given-names></name><name><surname>Carignan</surname><given-names>A</given-names></name><name><surname>Lesur</surname><given-names>O</given-names></name></person-group><article-title>Ventilator associated pneumonia and endotracheal tube repositioning: an underrated risk factor[J]</article-title><source>Am J Infect Control</source><year>2014</year><volume>42</volume><issue>12</issue><fpage>1328</fpage><lpage>1330</lpage><pub-id pub-id-type="doi">10.1016/j.ajic.2014.09.001</pub-id><pub-id pub-id-type="pmid">25465265</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schurink</surname><given-names>CA</given-names></name><name><surname>Van Nieuwenhoven</surname><given-names>CA</given-names></name><name><surname>Jacobs</surname><given-names>JA</given-names></name><name><surname>Rozenberg-Arska</surname><given-names>M</given-names></name><name><surname>Joore</surname><given-names>HC</given-names></name><name><surname>Buskens</surname><given-names>E</given-names></name><etal/></person-group><article-title>Clinical pulmonary infection score for ventilator-associated pneumonia:accuracy and inter-observer variability[J]</article-title><source>Intensive Care Med</source><year>2004</year><volume>30</volume><issue>2</issue><fpage>217</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1007/s00134-003-2018-2</pub-id><pub-id pub-id-type="pmid">14566455</pub-id></element-citation></ref></ref-list></back></article>